NCT03507543View on ClinicalTrials.gov

The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

February 3, 2017

Primary Completion Date

September 24, 2020

Study Completion Date

March 17, 2021

Conditions
Advanced Solid TumoursBreast CancerOvarian CancerProstate CancerPrimary Peritoneal Cancer
Interventions
DRUG

IMP4297

The dose levels will be escalated following a modified 3+3 dose escalation scheme.

Trial Locations (3)

2148

Blacktown Hospital, Blacktown

3004

Nucleus Network, Melbourne

Unknown

St George Private Hospital, Kogarah

Sponsors
All Listed Sponsors
lead

Impact Therapeutics, Inc.

INDUSTRY

NCT03507543 - The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter